Flag of the European Union EU Clinical Trials Register Help

Clinical trials for vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,995 result(s) found for: vaccine. Displaying page 23 of 100.
    «« First « Previous 19  20  21  22  23  24  25  26  27  Next» Last»»
    EudraCT Number: 2012-002428-34 Sponsor Protocol Number: 110478 Start Date*: 2015-04-30
    Sponsor Name:GlaxoSmithKline Biolgicals
    Full Title: A phase IV, partially double-blind, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as co...
    Medical condition: Booster immunisation of healthy children against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002861-11 Sponsor Protocol Number: FID01C Start Date*: 2007-08-10
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine administered by Intradermal Route (Flu-ID 15μg) versus a...
    Medical condition: prevention, vaccination against Influenza in subjects 65 years or older via intradermal route
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016794 Flu vaccination LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014770-17 Sponsor Protocol Number: NVI-255 Start Date*: 2009-10-09
    Sponsor Name:Netherlands Vaccine Institute
    Full Title: New influenza A (H1N1) disease incidence and immunogenicity of the pandemic influenza A (H1N1) vaccine in healthy adults
    Medical condition: influenza A (H1N1) virus infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002171-19 Sponsor Protocol Number: HEVACC Start Date*: 2021-05-12
    Sponsor Name:Medizinische Universität Innsbruck, Institut für Virologie
    Full Title: Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost
    Medical condition: Immunization for SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10021433 Immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005752-38 Sponsor Protocol Number: CBAF312ADE03 Start Date*: 2021-03-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC)
    Medical condition: secondary progressive multiple sclerosis (SPMS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003736-24 Sponsor Protocol Number: V503-069 Start Date*: 2021-03-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    21.1 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004153-10 Sponsor Protocol Number: H5N1/2005/01 Start Date*: 2005-09-22
    Sponsor Name:OTH - Chief Medical Officer's Office
    Full Title: Safety and immunogenecity of NIBRG-14 H5N1 01-2005 mock-up vaccine for potencial pandemic vaccine producers in Hungary
    Medical condition: Immunization of healthy people against influenza H5N1 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002529-31 Sponsor Protocol Number: VZVAC-TX Start Date*: 2020-08-20
    Sponsor Name:Oslo University Hospital
    Full Title: SAFETY AND EFFICACY OF SHINGRIX VACCINATION IN VARICELLA NAÏVE RENAL TRANSPLANT RECIPIENTS
    Medical condition: Kidney transplant recipients who are varicella-zoster sero-negative. The study aim to evaluate if the Shingrix vaccine will produce immune response in varicella naive kidney transplant recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000683-30 Sponsor Protocol Number: CoVacc Start Date*: 2021-03-03
    Sponsor Name:Umeå university
    Full Title: CoVacc - Immune response to vaccination against Covid-19, an open multicenter phase IV study
    Medical condition: Individuals with and without pre-existing immunity to Covid-19.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001228-32 Sponsor Protocol Number: COV002 Start Date*: 2020-05-04
    Sponsor Name:CTRG
    Full Title: A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-013054-33 Sponsor Protocol Number: V72P6E1 Start Date*: 2009-08-18
    Sponsor Name:Novartis Vaccines and Diagnostics Srl.
    Full Title: A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV N...
    Medical condition: The Novartis Meningococcal B recombinant vaccine is intended for prevention of meningitis and/or septicemia caused by Neisseria meningitidis serogroup B. The objective of the Novartis Meningococcal...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022538-10 Sponsor Protocol Number: 112688 Start Date*: 2011-04-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (Engerix-B™ Kinder) vaccine challenge in children...
    Medical condition: Antibody persistence and hepatitis B vaccine challenge in children aged 7–8 years, previously primed and boosted with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) as part of...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019731 Hepatitis B LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004903-63 Sponsor Protocol Number: V59P13E1 Start Date*: 2014-11-25
    Sponsor Name:Novartis Vaccines and Diagnostics Inc.
    Full Title: An Open-Label, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Adolescents Who Previously Received MenACWY-CRM Conjugate Vaccine or Menactra
    Medical condition: Novartis Meningococcal ACWY conjugate vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis serogroups A, C, W and Y.
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-002839-24 Sponsor Protocol Number: 108134 Start Date*: 2006-08-18
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A randomized, double-blind, placebo-controlled, multi-country and multi-center, phase IV study to demonstrate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscula...
    Medical condition: Immunization against influenza in male and female subjects aged 18 to 64 years
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-005083-15 Sponsor Protocol Number: V72_42 Start Date*: 2014-12-03
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 years in Korea.
    Medical condition: Prophylaxis Aganist Invasive Group B Meningococcal Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-003769-33 Sponsor Protocol Number: 103974, 104056 Start Date*: 2005-01-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III open (partially double-blind), controlled, multicenter, multicountry primary & booster vaccination study to demonstrate the non-inferiority of the meningococcal serogroup C response of ...
    Medical condition: Three-dose primary vaccination course with a haemophilus influenzae type B and meningococcal serogroup C conjugate vaccine of infants starting between 6 to 12 weeks of age with one month interval b...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001743-66 Sponsor Protocol Number: LSA3_1_06 Start Date*: 2007-09-20
    Sponsor Name:INSTITUT PASTEUR, Biomedical Parasitology Unit
    Full Title: Phase I and IIa trial to assess the safety, immunogenicity and protective efficacy against sporozoite challenge of the candidate malaria vaccine pfLSA-3 vaccine.
    Medical condition: P. falciparum infection (malaria)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003186-25 Sponsor Protocol Number: 205352 Start Date*: 2017-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Hea...
    Medical condition: Healthy volunteers (Infections, Meningococcal)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000482-21 Sponsor Protocol Number: B4671001 Start Date*: 2015-02-10
    Sponsor Name:Pfizer Inc
    Full Title: A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS GIVEN WITH ROUTINE PEDIATR...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001600-12 Sponsor Protocol Number: F/2004/2. Start Date*: 2004-09-20
    Sponsor Name:OMNINVEST Kft.
    Full Title: Fluval AB Vaccine Serologic Clinical Trial
    Medical condition: Immunization of healthy people against influenza virus infections.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 19  20  21  22  23  24  25  26  27  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 01:04:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA